Highest-materiality recent filing
FDA agreed that DLB psychosis is an approvable outcome; key aspects of Phase 3 trial design aligned.
Cognition Therapeutics presents at Jefferies; outlines registrational path for DLB psychosis
Cash ~$31.2M as of March 31, 2026; $25.6M remaining NIA grant funds; runway into Q2 2027.
Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis
FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.
Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20
Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.
Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine
Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.
Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting
Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.
Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.
Cognition Therapeutics raises ~$30.1M via registered direct offering of 14.7M shares at $2.05/share
Gross proceeds of $30.1M from sale of 14.7M shares at $2.05/share in a registered direct offering.
Cognition Therapeutics regains Nasdaq minimum bid price compliance
On Aug 26, 2025, Nasdaq confirmed Cognition Therapeutics regained compliance with the $1.00 minimum bid price rule.
Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones
Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.
Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial
Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.
Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's
Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.
Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.
Cognition Therapeutics gets Nasdaq extension to Sept 8, 2025; transfer to Capital Market
Received Nasdaq extension notice on March 12, 2025, granting 180 additional days until Sept 8, 2025 to regain $1.00 minimum bid price.
Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy
Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.
Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study
Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.
Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group
Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.
Cognition Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Deficiency letter received on September 12, 2024; stock continues trading under CGTX.
Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data
Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.
Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024
Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.
Cognition Therapeutics raises ~$10.4M in public offering of 6.57M shares at $1.75
Issued 6,571,428 shares of common stock at $1.75 per share; net proceeds ~$10.4M after expenses.
Cognition Therapeutics reports preliminary FY2023 net loss of $25.6M; cash at $29.9M
Preliminary net loss for FY2023 expected to be approximately $25.6 million.
Cognition Therapeutics announces positive Phase 2 SEQUEL topline results for CT1812 in Alzheimer's
Phase 2 SEQUEL study met primary safety and tolerability endpoints; CT1812 well-tolerated with no treatment-related SAEs.
Cognition Therapeutics Q1 net loss $6.2M; advances Alzheimer's and dry AMD trials
Net loss $6.2M ($0.21 per share) vs $3.8M ($0.17) in Q1 2022.
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
Completed enrollment in Phase 2 SEQUEL trial of CT1812 for mild-to-moderate Alzheimer's disease; topline results expected later 2023.
Mr. Doyle will succeed Mr. Andrew Einhorn, who has served as the Company’s Interim Chief Financial Officer since August 2022.
On May 1, 2023, Cognition Therapeutics, Inc. (the “ Company ”) announced the appointment of John Doyle as Chief Financial Officer of the Company, effective May 1, 2023.
the board of directors of the Company appointed Andrew Einhorn as Interim Chief Financial Officer, effective as of the Effective Date.
the Company determined that James O’Brien, the Company’s Chief Financial Officer, will be leaving the Company as of August 12, 2022
On October 29, 2021, Mark H. Breedlove notified the Board that he intends to resign as a member of the Board, effective December 31, 2021.
Effective November 1, 2021, in connection with the Board Increase, the Board appointed Ellen B. Richstone to serve as a Class I member of the Board
Max materiality 0.90 · Median 0.57 · Most common event other_material